BIOMEDICINES, INC. SEPTEMBER 12, 2000Investors' Rights Agreement • November 3rd, 2000 • Biomedicines Inc • California
Exhibit 10.11 BIOMEDICINES, INC. 909 Marina Village Parkway Alameda, California 94501 August 14, 1997 S. Mark Moran, M.D. 55 Orinda View Road Orinda, CA 94563 Re: Employment Agreement Dear Mark: BioMedicines, Inc. proposes to enter into the following...Employment Agreement • November 3rd, 2000 • Biomedicines Inc • California
EXHIBIT 10.5 LICENSE AGREEMENT THIS AGREEMENT (the "Agreement") is made and entered into this December 15, 1997 ("Effective Date") by and between G.D. SEARLE & CO., a Delaware corporation with offices at 5200 Old Orchard Road, Skokie, Illinois 60077...License Agreement • November 3rd, 2000 • Biomedicines Inc • California
RECITALSIndemnification Agreement • November 3rd, 2000 • Biomedicines Inc • Delaware
EXECUTEDLicense Agreement • November 3rd, 2000 • Biomedicines Inc
ATAMESTANE LICENSE AGREEMENTLicense Agreement • November 3rd, 2000 • Biomedicines Inc
Exhibit 10.9 MARINA VILLAGE FULL SERVICE OFFICE LEASE BASIC LEASE INFORMATION Date: DECEMBER 1, 1998Full Service Office Lease • November 3rd, 2000 • Biomedicines Inc
EXHIBIT 10.8 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. CONTRACT...Contract Research and Development Agreement • November 3rd, 2000 • Biomedicines Inc
ContractWarrant Agreement • April 20th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • California
THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.
OFFICE LEASEOffice Lease • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • California
THIS OFFICE LEASE (“Lease”) is made between SPIEKER PROPERTIES, L.P., a California limited partnership (“Landlord”), and BIOMEDICINES INC., a Delaware corporation (“Tenant”), as of February 21, 2001 (the “date of this Lease”).
Exhibit 10.12 November 23, 1999 S. Mark Moran, M.D. 55 Orinda View Road Orinda, CA 94563 RE: EMPLOYMENT AGREEMENT Dear Mark: This letter will serve to memorialize certain actions taken pursuant to, and modifications of, that certain Employment...Employment Agreement • November 3rd, 2000 • Biomedicines Inc
ATAMESTANE LICENSE AGREEMENTLicense Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
This agreement (“Agreement”) is made and entered into this 1st day of February 1999 by and between SCHERING AKTIENGESELLSCHAFT, a German corporation, with an address for purposes of this Agreement at Berlin-Wedding, Müllerstralbe 178, Berlin, Germany (“Schering”), and BIOMEDICINES, INC., a Delaware corporation, with an address for purposes of the Agreement at 909 Marina Village Parkway #583, Alameda, California, United States of America (U.S.) 94501 (“BioMedicines”).
CONTRACT RESEARCH AND DEVELOPMENT AGREEMENT ONContract Research and Development Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
This Contract Research And Development Agreement (“Agreement”) is made effective as of 17 July, 1998 (“Effective Date”), by and among BioMedicines, Inc. (“BioMedicines), a incorporated in the state of Delaware in the United States of America, having its principal business offices at 909 Marina Village Parkway No. 583, Alameda, CA 94501, and Boehringer Ingelheim Pharma KG (“BI Pharma KG”) a German corporation having a place of business at Birkendorfer Strabe 65, 88397 Biberach an der Riss, Federal Republic of Germany.
INTARCIA THERAPEUTICS, INC. INDEMNITY AGREEMENTIndemnification Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • Delaware
THIS AGREEMENT is made and entered into this day of , 200 by and between INTARCIA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Agent”).
5,000,000 Shares INTARCIA THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 16th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • New York
INTERIM DEVELOPMENT AGREEMENTInterim Development Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • California
This INTERIM DEVELOPMENT AGREEMENT (“Agreement”) is entered into as of this 8th day of November, 2000 between ALZA CORPORATION (“ALZA”) and BIOMEDICINES, INC. (“BioMedicines”).
LICENSE AGREEMENT ENDORECHERCHE Inc. BIOMEDICINES, Inc.License Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
This agreement (“Agreement”) is made and entered into this 4th of November 2002 by and between Endorecherche Inc, a Canadian corporation (“ERI”), with an address for purposes of the Agreement at 2989, rue de la Promenade Sainte-Foy G1W 2J5, Québec, Canada, and BioMedicines, Inc., a Delaware corporation (“BMI”), with an address for purposes of the Agreement at 2000 Powell Street, Ste 1640, Emeryville, CA, USA, 94608.
SECOND AMENDMENTLease Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT (the “Amendment”) is made and entered into as of the 26th day of September, 2003, by and between CA-EMERYVILLE PROPERTIES LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and BIOMEDICINES, INC., a Delaware corporation (“Tenant”).
Exhibit 10.7 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED LETTER...Omega Interferon License Agreement • November 3rd, 2000 • Biomedicines Inc
LICENSE AGREEMENTLicense Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • California
This LICENSE AGREEMENT executed this 7 day of November, 2002 is made by and between BioMedicines Inc., a Delaware corporation with principal offices located at 2000 Powell Street, Suite 1640, Emeryville, California 94608 (“BioMedicines”) and Chiron Corporation, a Delaware corporation with principal offices located at 4560 Horton Street, Emeryville, California 94608 (“Chiron”).
FIRST AMENDMENT TO LEASELease • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE (this “1st Amendment”) is made this 22nd day of March, 2001 between SPIEKER PROPERTIES, L.P., a California limited partnership, (“LANDLORD”), and BIOMEDICINES, INC., a Delaware corporation (“Tenant”).
AMENDMENT NO. I TO MARINA VILLAGE OFFICE LEASEMarina Village Office Lease • November 3rd, 2000 • Biomedicines Inc
OMEGA INTERFERON LICENSE AGREEMENT EXECUTEDLicense Agreement • May 16th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
OMEGA INTERFERON LICENSE AGREEMENT EXECUTEDLicense Agreement • April 20th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
LICENSE AGREEMENTLicense Agreement • April 20th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • California
This LICENSE AGREEMENT executed this 7 day of November, 2002 is made by and between BioMedicines Inc., a Delaware corporation with principal offices located at 2000 Powell Street, Suite 1640, Emeryville, California 94608 (“BioMedicines”) and Chiron Corporation, a Delaware corporation with principal offices located at 4560 Horton Street, Emeryville, California 94608 (“Chiron”).
INTARCIA THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT NOVEMBER 19, 2004Investors’ Rights Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 19th day of November, 2004, by and among INTARCIA THERAPEUTICS, INC., a Delaware corporation (the “Company”), the holders of the Company’s Series A Preferred Stock (the “Series A Preferred”), the Company’s Series B Preferred Stock (the “Series B Preferred”), the Company’s Series C Preferred Stock (the “Series C Preferred”) and the Company’s Series D Preferred Stock (the “Series D Preferred”) (hereinafter referred to as the “Prior Investors”) listed on Exhibit A hereto, the purchasers of the Company’s Series E Preferred Stock (the “Purchasers”) listed on Exhibit A hereto, and S. MARK MORAN (“Moran”). The Prior Investors and the Purchasers are referred to hereinafter as the “Investors” and each individually as an “Investor.”
TERM LOAN AND SECURITY AGREEMENTTerm Loan and Security Agreement • April 20th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations • California
The terms and information set forth on this cover page are a part of the attached Term Loan and Security Agreement, dated as of the date first written above (this “Agreement”), entered into by and among, SILICON VALLEY BANK, a California-chartered bank, with its principal place of business at 3003 Tasman Drive, Santa Clara, California (“SVB”), as Agent, and the Lenders, including without limitation, SVB and HORIZON TECHNOLOGY FUNDING COMPANY LLC, a Delaware Limited Liability Company, with its principal place of business at 76 Batterson Park Road, Farmington, Connecticut 06032 (“Horizon”) and INTARCIA THERAPEUTICS, INC., a Delaware corporation, with its chief executive office located at 2000 Powell Street, Suite 1640, Emeryville, California 94608 (“Borrower”). The terms and conditions of this Agreement agreed to between the parties hereto are as follows:
EXHIBIT 10.16 CONSULTING AGREEMENT Agreement ("AGREEMENT") dated 1 May, 1999 between Dr. Hana Berger Moran ("CONSULTANT") and BioMedlcines, Inc. ("BIOMEDICINES"), a Delaware corporation having an address for purposes of this AGREEMENT at 1301 Marina...Consulting Agreement • November 3rd, 2000 • Biomedicines Inc • California
OMEGA INTERFERON LICENSE AGREEMENT EXECUTEDLicense Agreement • February 7th, 2005 • Intarcia Therapeutics, Inc • Pharmaceutical preparations
This agreement (“Agreement”) is made and entered into this July 17, 1998 by and between BOEHRINGER INGELHEIM INTERNATIONAL GMBH, a corporation with offices at D 55216 Ingelheim/Rhein, Germany (“BII”), and BIOMEDICINES, INC., a Delaware corporation, with an address for purposes of the Agreement at 909 Marina Village Parkway #583 Alameda, California, United States of America (U.S.A.) 94501 (“BMI”).
RECITALSInterim Development Agreement • February 20th, 2001 • Biomedicines Inc • Pharmaceutical preparations • California
